| human | Q5 |
| P496 | ORCID iD | 0000-0003-1071-7956 |
| P69 | educated at | University of Melbourne | Q319078 |
| University of Queensland | Q866012 | ||
| P108 | employer | Peter MacCallum Cancer Centre | Q7175569 |
| Sir Charles Gairdner Hospital | Q7526207 | ||
| P735 | given name | Peter | Q2793400 |
| Peter | Q2793400 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q61800982 | A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy |
| Q47926878 | A pilot study to assess the validity of the DASS-21 subscales in an outpatient oncology population. |
| Q92667432 | Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis |
| Q112281437 | Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma |
| Q83355653 | Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection |
| Q64273791 | Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series |
| Q104281755 | Combined BRAF, MEK and CDK4/6 inhibition depletes intratumoral immune-potentiating myeloid populations in melanoma |
| Q51307035 | Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. |
| Q41816697 | Marked functional improvement after combined chemoradiotherapy for cervical spine glioblastoma causing quadriparesis in an adolescent |
| Q85364776 | Patients prefer chemotherapy on the same day as their medical oncology outpatient appointment |
| Q92796910 | Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma |
| Q93140337 | Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series |
| Q45935659 | The evaluation of a clinical scar scale for porcine burn scars. |
| Q49694802 | Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. |
Search more.